Prognostic value of inflammatory cytokine levels, clinical efficacy, and prognosis of the hybrid artificial liver support system in chronic liver failure treatment

The combination of PEG and DPMAS (HALSS) demonstrated superior clinical efficacy in improving liver and kidney function, reducing inflammation, and enhancing patient prognosis compared to single therapies. These findings support HALSS as a promising adjunctive therapy for CLF patients, improving short-term outcomes and long-term survival.